TGF-β2-treated equine MSCs have decreased cell-mediated cytotoxicity

Our most recent paper has been published in Frontiers in Cell and Developmental Biology! The study shows that allogeneic MHC-mismatched equine bone marrow-derived mesenchymal stem cells treated with TGF-β2 had significantly reduced cell-mediated cytotoxicity in vitro. The TGF-β2 treatment did not affect the ability of equine MSCs to inhibit allorecognition and lymphocyte proliferation or secrete PGE2 and TGF-β1, which are essential for their therapeutic potential.

This work was supported by the Morris Animal Foundation and the National Institutes of Health.

Read the full paper here or learn more about the translational impacts of the research here.


Berglund, Long, Robertson, and Schnabel. 2021. Frontiers Cell Dev Biol.


Published in News.